Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 4/20 | 0.80 |
| ▸ | CA1 | P00915 | 3/20 | 0.80 |
| ▸ | ENPP2 | Q13822 | 9/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | LPL | P06858 | 1/20 | 0.46 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.46 |
| ▸ | TTR | P02766 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | CA4 | P22748 | 1/20 | 0.43 |
| ▸ | CA6 | P23280 | 1/20 | 0.43 |
| ▸ | CA5A | P35218 | 1/20 | 0.43 |
| ▸ | CA7 | P43166 | 1/20 | 0.43 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.43 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31354846 | 1.00 | CA2 (0.80) | CA2CA1ENPP2TSHRLPL | |
| SCHEMBL13667343 | 0.94 | CA2 (0.73) | CA2CA1ENPP2TSHRLPL | |
| SCHEMBL28784898 | 0.91 | CA2 (0.76) | CA2CA1ENPP2TSHRLPL | |
| SCHEMBL23150 | 0.89 | CA1 (1.00) | CA2CA1ENPP2KDM4EALDH1A1 | |
| SCHEMBL29612616 | 0.89 | CA1 (1.00) | CA2CA1ENPP2KDM4EALDH1A1 | |
| SCHEMBL29956431 | 0.87 | CA1 (0.64) | CA2CA1ENPP2TSHRTTR | |
| SCHEMBL29952033 | 0.87 | CA1 (0.86) | CA2CA1ENPP2KDM4EALDH1A1 | |
| SCHEMBL21352794 | 0.87 | CA1 (0.86) | CA2CA1ENPP2KDM4EALDH1A1 | |
| SCHEMBL1153498 | 0.87 | CA1 (0.86) | CA2CA1ENPP2KDM4EALDH1A1 | |
| SCHEMBL16547259 | 0.87 | CA2 (0.64) | CA2CA1ENPP2TSHRLPL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118085886-A | Preparation method of terphenyl phenanthrene discotic liquid crystal compound | 四川师范大学 | 2024-05-28 | — | — | CN | disclosed |
| WO-2023206360-A1 | SECONDARY BATTERY AND BATTERY MODULE COMPRISING SAME, BATTERY PACK, AND ELECTRICAL DEVICE | 宁德时代新能源科技股份有限公司 | 2023-11-02 | — | — | WO | disclosed |
| WO-2023206427-A1 | SECONDARY BATTERY, BATTERY MODULE COMPRISING SAME, BATTERY PACK, AND ELECTRIC DEVICE | 宁德时代新能源科技股份有限公司 | 2023-11-02 | — | — | WO | disclosed |
| US-20230263058-A1 | ORGANIC COMPOUND AND ORGANIC LIGHT-EMITTING ELEMENT | CANON KABUSHIKI KAISHA (JP) | 2023-08-17 | — | — | US | disclosed |
| US-20230263058-A1 | ORGANIC COMPOUND AND ORGANIC LIGHT-EMITTING ELEMENT | CANON KABUSHIKI KAISHA (JP) | 2023-08-17 | — | — | US | disclosed |
| EP-3626716-A1 | ANTIVIRAL COMPOUNDS | Gilead Pharmasset LLC (US) | 2020-03-25 | — | — | EP | disclosed |
| US-10273339-B2 | Synthesis of a highly crystalline, covalently linked porous network | UNIVERSITY OF SOUTH CAROLINA (US) | 2019-04-30 | — | — | US | disclosed |
| US-9981955-B2 | Antiviral compounds | GILEAD PHARMASSET LLC (US) | 2018-05-29 | — | — | US | disclosed |
| EP-3309157-A1 | ANTIVIRAL COMPOUNDS | Gilead Pharmasset LLC (US) | 2018-04-18 | — | — | EP | disclosed |
| EP-1957606-B1 | NOVEL MATERIALS FOR ORGANIC ELECTROLUMINIESCENT DEVICES | MERCK PATENT GMBH (DE) | 2017-11-08 | — | — | EP | disclosed |
| WO-2010132601-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2010-11-18 | — | — | WO | disclosed |
| WO-2010119276-A1 | ORGANIC LIGHT-EMITTING MATERIALS AND DEVICES | CAMBRIDGE DISPLAY TECHNOLOGY LIMITED (GB) | 2010-10-21 | — | — | WO | disclosed |
| US-7795443-B2 | Compound and organic thin film transistor | CANON KABUSHIKI KAISHA (JP) | 2010-09-14 | — | — | US | disclosed |
| US-7795443-B2 | Compound and organic thin film transistor | CANON KABUSHIKI KAISHA (JP) | 2010-09-14 | — | — | US | disclosed |
| WO-2009127896-A1 | SYNTHESIS OF AN ORDERED COVALENT MONOLAYER NETWORK ONTO A SURFACE | UNIVERSITE D'AIX-MARSEILLE I (FR) | 2009-10-22 | — | — | WO | disclosed |
| US-20090227697-A1 | SYNTHESIS OF A HIGHLY CRYSTALLINE, COVALENTLY LINKED POROUS NETWORK | NATIONAL SCIENCE FOUNDATION | 2009-09-10 | — | — | US | disclosed |
| US-20080303423-A1 | Novel Materials For Organic Electroluminescent Devices | MERCK PATENT GMBH (DE) | 2008-12-11 | — | — | US | disclosed |
| US-20080303423-A1 | Novel Materials For Organic Electroluminescent Devices | MERCK PATENT GMBH (DE) | 2008-12-11 | — | — | US | disclosed |
| US-20080241594-A1 | NOVEL COMPOUND AND ORGANIC THIN FILM TRANSISTOR | CANON KABUSHIKI KAISHA (JP) | 2008-10-02 | — | — | US | disclosed |
| US-20080241594-A1 | NOVEL COMPOUND AND ORGANIC THIN FILM TRANSISTOR | CANON KABUSHIKI KAISHA (JP) | 2008-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080241594-A1 | NOVEL COMPOUND AND ORGANIC THIN FILM TRANSISTOR | TMX1, TCOF1, TTI1 | CA2 1289/4885CA1 259/4885ENPP2 2971/4885 |
| US-20230263058-A1 | ORGANIC COMPOUND AND ORGANIC LIGHT-EMITTING ELEMENT | NR2E3, LGR4, NCOA4 | CA2 3559/4885CA1 3922/4885ENPP2 2364/4885 |
| US-10273339-B2 | Synthesis of a highly crystalline, covalently linked porous network | PARN, PARG, PUF60 | CA2 1405/4885CA1 393/4885ENPP2 2526/4885 |
| US-20080303423-A1 | Novel Materials For Organic Electroluminescent Devices | ANXA2, ANXA7, ANXA1 | CA2 2347/4885CA1 1586/4885ENPP2 926/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.